drugset
drugset / Trial / NCT06646627

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

NCT06646627 ↗

Phase 1 Recruiting 48 enrolled Stanford University
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

Timeline

Start
2024-11-11
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject B7-H3CART Cell therapy 300000 cells/kg Other
Subject B7-H3CART Cell therapy 1e+06 cells/kg Other
Subject B7-H3CART Cell therapy 3e+06 cells/kg Other
Subject B7-H3CART Cell therapy 1e+07 cells Other
Subject B7-H3CART Cell therapy 1e+07 cells/kg Other
Subject B7-H3CART Cell therapy 5e+07 cells Other
Subject B7-H3CART Cell therapy 1.5e+08 cells Other
Subject B7-H3CART Cell therapy 5e+08 cells Other

Indications

ovarian cancer